GreenLight Biosciences Announces Series D Financing, Unveils RNA Strategy

GreenLight Biosciences, Inc. announced today the completion of its $18 million Series D round of financing led by Fall Line Capital. S2G Ventures, Lewis and Clark Ventures, and Macro Capital Investments participated in the round, along with the majority of GreenLight’s existing investors, including Kodiak Venture Partners, MLSCF, Syngenta Ventures and others.  GreenLight is harnessing its Cell-Free Bioprocessing® platform to develop a portfolio of RNA-based products for use in agriculture.

Read the full article, here.